Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019, with a filing date of October 15, 2019. The document serves as a transaction notification under Rule 13a-16 or 15d-16, detailing share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transaction data:
- Transaction Type: Acquisition of Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ADSs) (ISIN: US37733W1053).
- Transaction Nature: All transactions were acquisitions resulting from the re-investment of dividends paid to shareholders on October 10, 2019.
- Transaction Date: October 11, 2019.
- Transaction Venues: London Stock Exchange (XLON) for Ordinary Shares and New York Stock Exchange (XNYS) for ADSs.
- Share Prices: Ordinary Shares were acquired at £16.6032; ADSs were acquired at $42.2439.
Material Changes
The filing does not contain comparative financial data or material changes in the company's operational or financial performance versus prior periods. The only reported activity is the routine re-investment of dividends by executive officers and their associates.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Important Facts for Investor Verification
- Verify that the share acquisitions listed were strictly for dividend re-investment plans and not open-market purchases.
- Confirm the dividend payment date of October 10, 2019, aligns with the company's declared dividend schedule.
- Note that the filing includes transactions for both UK-listed Ordinary Shares and US-listed ADSs.
- Recognize that this document contains no information regarding GSK's overall financial health or strategic outlook for 2019.